Citigroup
AKBA icon

Citigroup’s Akebia Therapeutics AKBA Stock Holding History

Citigroup’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-275,000
Closed -$197K – 6196
2022
Q1 		$197K Buy
275,000
+25,000
+10% +$53.5K ﹤0.01% 4086
2021
Q4 		$565K Buy
+250,000
New +$682K ﹤0.01% 3700
2020
Q1 		– Sell
-2,997
Closed -$19K – 7577
2019
Q4 		$19K Hold
2,997
– – ﹤0.01% 6944
2019
Q3 		$12K Hold
2,997
– – ﹤0.01% 6977
2019
Q2 		$15K Hold
2,997
– – ﹤0.01% 7178
2019
Q1 		$25K Sell
2,997
-4,403
-60% -$30.2K ﹤0.01% 6826
2018
Q4 		$41K Buy
+7,400
New +$57.9K ﹤0.01% 6391

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup's AKBA Position: Q2 2026 in Review

Citigroup reduced its Akebia Therapeutics (AKBA) stake by 61% in Q2 2026, selling an estimated $2.06M and leaving 1,124,570 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3269.

Citigroup first reported a position in AKBA in Q2 2014 and has held it in 49 quarters since. The position peaked at $8.26M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Citigroup held 1,124,570 shares of Akebia Therapeutics worth $1.28M as of Q2 2026.
  • Citigroup sold 1,730,016 Akebia Therapeutics shares in Q2 2026, an estimated $2.06M.
  • Akebia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3269 holding.
  • Citigroup first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 49 quarters since.
  • Citigroup's Akebia Therapeutics position peaked at $8.26M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.